Document is current

Article History

Received: 26 October 2024

Accepted: 19 February 2025

First Online: 28 February 2025

Declarations

:

: Human WJ-MSCs from a single donor, which were collected with informed consent for the use of the study, were provided by the Samsung Medical Center Good Manufacturing Practice Facility (IRB approval number: 2016-07-102-043; Date of approval: 2016-09-20; Approval expiration date: 2025-09-15; Study name: Study on the Selection of Optimal Mesenchymal Stem Cells from Different Sources for the Treatment of Chronic/Intractable Diseases including Alzheimer’s Disease and Musculoskeletal Disorders). All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (Approval numbers: 20231115001 and 20230116001. Approval Date: 2023.12.22 and 2023.02.22) of the Samsung Biomedical Research Institute, an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility, following the National Institutes of Health Guidelines for Laboratory Animal Care. Animal studies followed the ARRIVE guidelines.

: Not applicable.

: The funders had no role in the study design; collection, analyses, or interpretation of data; writing of the manuscript; or decision to publish the results. Yun Sil Chang, Se In Sung, Young Eun Kim, Sein Hwang, and Ara Koh declare potential conflicts of interest arising from an issued patent titled “A composition for the prevention and treatment of necrotizing enterocolitis containing extracellular vesicles derived from thrombin-treated mesenchymal stem cells” (10-2024-0051684) as co-inventors, not as patentees.